Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$314.00K$314.00K— vs Q3 2020 Net Income-$5.30M-$5.30MN/M vs Q3 2020 EPS Diluted-$0.07-$0.07N/M vs Q3 2020 Operating Income-$5,299,300N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1687.7%
Net margin-1687.5%
ended Dec 31, 2020 · filed Feb 11, 2021 · 42 d after period end